Loading stock data…
$4.41-0.45 (-9.35%)
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible.
Entrada Therapeutics, Inc. in the Healthcare sector is trading at $4.41 with a market capitalization of $265M. Wall Street consensus targets $19.00 (4 analysts), implying a +331.3% move over the next 12 months. The stock is currently near its 52-week low of $4.11, remaining 51.6% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 20 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $898,000↑ | $875,000↓ | $1.30M↓ | $1.61M↓ | $1.95M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$44.96M↓ | -$42.30M↓ | -$42.21M↑ | -$47.05M↓ | -$46.85M |
| Net Income | -$42.76M↓ | -$39.72M↓ | -$39.16M↑ | -$44.13M↓ | -$43.10M |
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's ...